Filing Flows › Emmaus Life Sciences (EMMA) › Q1 2026 › vs Q4 2025
Emmaus Life Sciences (EMMA) Q1 2026 vs Q4 2025 (quarter over quarter)
Emmaus Life Sciences's revenue fell $1.9M (-49%) from $3.9M in Q4 2025 to $2.0M in Q1 2026.
Emmaus Life Sciences, Q1 2026: revenue $2.0M (-18% year over year), operating margin -41.5%, net loss $3.3M, operating cash flow −$344K. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $2.0M | $3.9M | −$1.9M | -49% |
| Net loss | $3.3M | $2.0M | $1.4M | +71% |
| Costs & expenses | $5.3M | $5.8M | −$486K | -8% |
| Operating costs | $2.8M | $3.0M | −$161K | -5% |
| Interest & other, net | $2.5M | $2.8M | −$313K | -11% |
| Income tax | $4K | $16K | −$12K | -75% |
| Cost of revenue | $168K | $235K | −$67K | -29% |
| Research & development | $40K | $31K | $9K | +29% |
| Sales & marketing | $747K | $898K | −$151K | -17% |
| General & admin | $1.9M | $1.8M | $48K | +3% |
| Operating cash sources | $3.3M | $2.0M | $1.4M | +71% |
| Depreciation | $15K | $15K | $0 | 0% |
| Share-based compensation | $1K | $7K | −$6K | -86% |
| Working capital & other | $3.0M | $4.1M | −$1.2M | -28% |
| Cash used in operations | $344K | −$2.2M | $2.6M | — |
| Net loss absorbed | $3.3M | $2.0M | $1.4M | +71% |
Questions
How much did Emmaus Life Sciences's revenue grow quarter over quarter in Q1 2026?
Emmaus Life Sciences's revenue fell $1.9M (-49%) from $3.9M in Q4 2025 to $2.0M in Q1 2026.